TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Programmed death-1 (PD-1) is a coinhibitory receptor that suppresses T-cell activity in cancer and chronic infections.
• The mechanisms driving high PD-1 expression on tumor-infiltrating lymphocytes (TILs) are not fully understood.
• Transforming growth factor beta (TGFβ) is known to affect T-cell function, but its role in PD-1 regulation within the tumor microenvironment (TME) requires further investigation.

Purpose of the Study:

• To investigate the molecular mechanisms by which TGFβ1 influences PD-1 expression on TILs.
• To determine the role of SMAD3 in TGFβ1-mediated PD-1 upregulation.
• To assess the impact of TGFβ1-induced PD-1 expression on T-cell function and antitumor immunity.

Main Methods:

• In vitro studies using T cells and in vivo studies using TILs.
• Analysis of antigen-induced PD-1 expression.
• Assessment of SMAD3-dependent and SMAD2-independent transcriptional activation.
• Evaluation of PD-1 expression in Smad3-deficient tumor-specific CD8+ TILs.
• Measurement of cytokine production and antitumor activity.

Main Results:

• TGFβ1 enhances antigen-induced PD-1 expression on T cells and TILs through a SMAD3-dependent, SMAD2-independent pathway.
• The PD-1-high subset of CD8+ TILs is absent in Smad3-deficient TILs.
• Smad3 deficiency in TILs leads to enhanced cytokine production and antitumor activity.
• TGFβ1 mediates T-cell suppression in the TME by upregulating PD-1 on TILs.
• Bidirectional cross-talk between TILs and TGFβ-producing cells upregulates PD-1 signaling components, inhibiting antitumor immunity.

Conclusions:

• TGFβ1 plays a novel immunosuppressive role by enhancing PD-1 expression on TILs via SMAD3.
• This mechanism contributes to tumor immune evasion by inhibiting antitumor T-cell function.
• Targeting the TGFβ1-SMAD3-PD-1 axis represents a potential strategy to enhance cancer immunotherapy.